Investment Summary

Shore Capital Partners Invests In Argentum

On January 25, 2017, private equity firm Shore Capital Partners invested in medical products company Argentum

Investment Highlights
  • This is Shore Capital Partners’ 5th transaction in the Medical Products sector.
  • This is Shore Capital Partners’ 18th transaction in the United States.
  • This is Shore Capital Partners’ 3rd transaction in Illinois.
Investment Fate
  • Argentum was sold to a strategic buyer in 2023.

Investment Summary

Date 2017-01-25
Target Argentum
Sector Medical Products
Investor(s) Shore Capital Partners
Deal Type Growth Capital
Advisor(s) The Walden Group, Inc. (Financial)

Target

Argentum

Geneva, Illinois, United States
website
Argentum is a manufacturer and sells innovative wound care products across a wide number of clinical applications, including the Silverlon® (“Silverlon”) brand, its rapidly-growing, proprietary range of silver-based antimicrobial products. The core platform technology in Silverlon is a uniquely designed silver-plated nylon matrix that provides the powerful antimicrobial properties of silver ions in the dressing without staining the skin and without increasing bioburden. Silverlon dressings are used today by surgeons and other healthcare professionals around the world on surgical wounds, burns, chronic wounds, IV catheter-related wounds, and for negative pressure wound therapy. Argentum was founded in 2001 and is based in Geneva, Illinois.

Search 191,421 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Shore Capital Partners

Chicago, Illinois, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2009
PE ASSETS 350M USD
Size Middle-Market
Type Sector Focused
DESCRIPTION

Shore Capital Partners is a private equity group focused on opportunities in healthcare, food/beverages, and business services. Specific healthcare areas of interest include infusion therapy, laboratory services, laboratory products/distribution, outpatient rehab therapy, and behavioral health. Shore looks to invest in proven businesses with stable cash-flows and 'significant' growth potential. Prospective companies typically have $5 to $50 million in sales and $1 to $7 million of EBITDA. Shore Capital was formed in 2009 and is based in Chicago, Illinois.


DEAL STATS #
Overall 18 of 50
Sector (Medical Products) 5 of 6
Type (Growth Capital) 5 of 8
State (Illinois) 3 of 11
Country (United States) 18 of 49
Year (2017) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-03 ClearPath Diagnostics

Syracuse, New York, United States

ClearPath Diagnostics is a provider of anatomic pathology practice and laboratory in New York which primarily serves the women's health market. ClearPath provides service to thousands of physicians throughout the Northeastern United States.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-14 EyeSouth Partners

Atlanta, Georgia, United States

EyeSouth Partners is an eye care physician services organization committed to partnering with leading physicians to build a premier network of eye care services in Georgia and the Southeast. EyeSouth’s partner practices’ clinical mission is to provide high-quality medical and surgical specialty eye care. The organization supports its affiliated practices and physician partners with capital, administrative resources, operating expertise, and strategic guidance with an absolute focus on clinical quality and a patient-first culture. EyeSouth Partners was formed in 2017 and is based in Atlanta, Georgia.

Buy -